A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer

NCT00190840 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

186

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small Cell Lung

Interventions

DRUG: pemetrexed

Sponsor

Eli Lilly and Company